medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 3

<< Back Next >>

Ann Hepatol 2011; 10 (3)

Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient

Bahde R, Hölzen JP, Wolters HH, Schmidt HHJ, Bock CT, Lügering A, Spieker T, Senninger N, Brockmann JG

Language: English
References: 25
Page: 355-360
PDF size: 204.43 Kb.


ABSTRACT

The increasing demand for transplantation has led to consideration of liver grafts from donors exposed to hepatitis B virus (HBV). Six transplantations of liver grafts from hepatitis B surface antigen (HBsAg) positive donors have been reported; two recipients suffered from HBV/HDV (hepatitis Delta virus) coinfection and were followed up for 10-12 months. Here, we report a 56 months follow-up of a HBV/HDV-coinfected recipient of a HBsAg positive liver graft. Posttransplant combination prophylaxis consisted of hepatitis immunoglobulin, lamivudine and adefovir dipivoxil. HBsAg remained positive during stable posttransplant follow-up and subclinical HDV reinfection with low replication rate was detected at 1 month. Pegylated interferon therapy was introduced after documentation of histological evidence of mild chronic hepatitis, but without virological response after 48 weeks. Finally, antiviral treatment was switched to tenofovir disoproxil fumarate. More than 50 months posttransplant the recipient revealed clinical symptoms of decompensated liver cirrhosis and has been relisted for liver transplantation. In conclusion HBsAg positive liver grafts in HBsAg positive recipients with HDV coinfection may result in virological recurrence and rapid development of liver cirrhosis.


REFERENCES

  1. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: A survery of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009; 15: 223-32.

  2. Gonzalez-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, Lau JY. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus- negative recipient. Transplantation 1994; 58: 114-16.

  3. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-8.

  4. Hwang SH, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, Moon DB, et al. Five-year follow-up of a hepatitis B virus-positive recipient of a hepatitis B surface antigen-positive living donor liver graft. Liver Transpl 2006; 12: 993-7.

  5. Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, Nakamuta M, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int 2007; 27: 1282-6.

  6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.

  7. Rizetto M. Hepatitis D: Clinical features and therapy. Dig Dis 2010; 28: 139-43.

  8. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39: S212–S19.

  9. Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Aricò S, Calzia R, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98: 437-41.

  10. Rifai K, Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL. Longer survival of liver transplant recipients with hepatits virus coinfections. Clin Transplant 2007; 21: 258-64.

  11. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Eng J Med 1993; 329: 1842-7.

  12. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi- Venon W, Alessandria C, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transplant 2005; 11: 402-9.

  13. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85.

  14. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF, Gigou M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-9.

  15. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.

  16. Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH, Rizzetto M, et al. Hepatitis D viremia following or thotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998; 27: 1723-9.

  17. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, Verran D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globuline. Liver Transpl Surg 1999; 5: 512-19.

  18. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.

  19. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005; 12: 2-9.

  20. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot- Peignoux M, Boyer N, Pham BN, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-35.

  21. Erhardt A, Gerlich W, Starke C Wend U, Donner A, Sagir A, Heintges T, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-10.

  22. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, et al. Long-term efficacy of tenofovir monotherapy for hepatits B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.

  23. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010 Sep 3 (Epub ahead of print).

  24. Mansour W, Ducancelle A, Le Gal F, Le Guillou-Guillemette H, Abgueguen P, Pivert A, Calès P, et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010; 47: 97-9.

  25. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus (HDV). J Clin Invest 2003; 112: 407-14.




2020     |     www.medigraphic.com